- Home
- APPS vs LAB Comparison
APPS vs LAB Comparison
Compare APPS & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APPS | LAB |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Laboratory Analytical Instruments |
| Sector | Miscellaneous | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.7M | 488.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | APPS | LAB |
|---|---|---|
| Price | $4.19 | $1.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $6.25 | $1.35 |
| AVG Volume (30 Days) | ★ 4.1M | 1.1M |
| Earning Date | 02-03-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $541,854,000.00 | $169,737,000.00 |
| Revenue This Year | $13.99 | N/A |
| Revenue Next Year | $11.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.05 | ★ 79.77 |
| 52 Week Low | $2.11 | $0.92 |
| 52 Week High | $8.28 | $1.72 |
Technical Indicators
Market Signals| Indicator | APPS | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 30.12 |
| Support Level | $3.97 | $1.24 |
| Resistance Level | $4.80 | $1.46 |
| Average True Range (ATR) | 0.46 | 0.07 |
| MACD | -0.10 | -0.03 |
| Stochastic Oscillator | 9.68 | 4.76 |
Price Performance
Historical ComparisonAbout APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.